EXENATIDE SYNTHETIC
Clinical safety rating
safeAnimal studies have demonstrated safety
Exenatide synthetic is a glucagon-like peptide-1 (GLP-1) receptor agonist. It mimics the incretin hormone GLP-1, enhancing glucose-dependent insulin secretion from pancreatic beta cells, suppressing glucagon secretion, slowing gastric emptying, and promoting satiety.
| Metabolism | Exenatide is primarily degraded by proteolytic degradation (neutral endopeptidase) and renal filtration, with minimal hepatic metabolism. |
| Excretion | Primarily renal via glomerular filtration and proteolytic degradation; approximately 30% of the dose is excreted unchanged in urine, with the remainder as metabolites in urine and feces. |
| Half-life | Terminal elimination half-life is 2.4 hours for subcutaneous administration, supporting twice-daily dosing. |
| Protein binding | Approximately 25% bound to plasma proteins, primarily albumin. |
| Volume of Distribution | Volume of distribution is 0.2 L/kg, indicating limited extravascular distribution. |
| Bioavailability | Subcutaneous: absolute bioavailability is approximately 65%. |
| Onset of Action | Subcutaneous: onset of glucose-lowering effect within 30 minutes. |
| Duration of Action | Duration of action is approximately 8-10 hours after a single subcutaneous dose, consistent with twice-daily dosing. |
| Molecular Weight | 4186.6 |
Subcutaneously 5 mcg twice daily within 60 minutes before morning and evening meals; may increase to 10 mcg twice daily after 1 month.
| Dosage form | INJECTABLE |
| Renal impairment | CrCl 30-50 mL/min: no adjustment; CrCl <30 mL/min: not recommended; ESRD on dialysis: contraindicated. |
| Liver impairment | No specific adjustment for mild to moderate hepatic impairment; not studied in severe impairment (Child-Pugh C). |
| Pediatric use | Not approved for use in pediatric patients; safety and efficacy not established. |
| Geriatric use | No specific dose adjustment; use caution due to increased risk of renal impairment and hypoglycemia; monitor renal function. |
| 1st trimester | Exenatide is not recommended during the first trimester due to lack of adequate human studies and potential risk of fetal harm based on animal studies showing decreased fetal growth and increased skeletal variations at clinically relevant doses. |
| 2nd trimester | Available data do not establish safety; expert opinion advises against use due to potential for altered maternal metabolism affecting fetal development. Use only if clearly needed and potential benefit justifies potential risk to fetus. |
| 3rd trimester | Use in third trimester may cause neonatal hypoglycemia from maternal hyperglycemia reversal and potential metabolic disturbances. Avoid unless otherwise indicated. |
Clinical note
Drugs that are rapidly absorbed may be delayed (eg antibiotics) Can cause nausea and increased risk of thyroid C-cell tumors in rodents.
| Placental transfer | Exenatide is a large peptide (MW 4186.6 Da) and is expected to cross the placenta to a limited extent; however, due to its molecular size and protein binding, placental transfer is likely low. Animal studies show evidence of transfer but human data are limited. |
| Breastfeeding | Exenatide is excreted in human milk in low amounts; however, because of the low oral bioavailability of exenatide in infants, ingestion via breast milk is unlikely to produce clinically relevant effects. Caution should be exercised; risk-benefit assessment recommended. |
| Lactation Rating | L3 (Moderately Safe) |
| Teratogenic Risk | Pregnancy Category C. In animal studies, exenatide caused reduced fetal growth, decreased ossification, and increased incidence of skeletal abnormalities at doses 5-13 times human exposure. No adequate human studies. Risk cannot be ruled out; use only if potential benefit justifies potential risk to fetus. |
| Fetal Monitoring | Monitor maternal blood glucose, weight, HbA1c. Assess for gastrointestinal adverse effects (nausea, vomiting) which may affect nutrition. Monitor fetal growth and well-being (ultrasound) as indicated for gestational diabetes or other high-risk conditions. |
| Fertility Effects | Animal studies: exenatide did not impair fertility at doses up to 130 times human exposure. Human data: no specific studies on fertility effects. GLP-1 receptor agonists may improve metabolic parameters that could affect fertility in patients with PCOS or obesity. |
■ FDA Black Box Warning
No black box warning.
| Common Effects | Constipation Headache High blood pressure Nasal inflammation Urinary tract infection Fast heart rate Joint pain |
| Serious Effects |
Personal or family history of medullary thyroid carcinomaMultiple endocrine neoplasia syndrome type 2 (MEN 2)Severe gastrointestinal disease (e.g., gastroparesis)Known hypersensitivity to exenatide or any product componentsType 1 diabetes mellitus (not indicated)
| Precautions | Risk of acute pancreatitis; discontinue if suspected, Risk of hypoglycemia when used with insulin secretagogues or insulin, Renal impairment: increased risk of gastrointestinal adverse effects and acute renal failure; avoid in end-stage renal disease, Severe gastrointestinal disease: may exacerbate gastroparesis, Thyroid C-cell tumors: observed in rodent studies; monitor for serum calcitonin or thyroid masses, Immunogenicity: may develop anti-exenatide antibodies leading to loss of efficacy or injection site reactions |
| Food/Dietary | Exenatide slows gastric emptying, which may reduce the rate and extent of absorption of oral medications. Take exenatide at least 1 hour before meals; for oral medications requiring rapid absorption (e.g., antibiotics, oral contraceptives), take them 1 hour before or 4 hours after exenatide. No specific food restrictions, but high-fat meals may increase nausea. |
| Clinical Pearls | Exenatide is a GLP-1 receptor agonist used for T2DM. It slows gastric emptying, so administer at least 60 min before first meal of day. Avoid in severe renal impairment (CrCl <30 mL/min). Risk of acute pancreatitis; discontinue if suspected. Not for use in T1DM or DKA. Monitor for thyroid C-cell tumors (contraindicated if personal/family history of MTC or MEN 2). |
| Patient Advice | Inject subcutaneously in abdomen, thigh, or upper arm, within 60 minutes before morning and evening meals (or before the two main meals of the day, at least 6 hours apart). · Do not administer after a meal; skip dose if a meal is skipped. · Store unused pens in refrigerator (36°F to 46°F). In-use pen can be kept at room temperature up to 86°F for up to 30 days. · Common side effects include nausea, vomiting, diarrhea, and headache; these often decrease over time. · Seek medical attention for severe abdominal pain (possible pancreatitis), rash or hives, difficulty breathing, or swelling of face/ lips (angioedema). |
Loading safety data…